Stock 600535 TASLY PHARMACEUTICAL GROUP CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tasly Pharmaceutical Group Co., Ltd

Equities

600535

CNE000001C81

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
15.36 CNY +3.09% Intraday chart for Tasly Pharmaceutical Group Co., Ltd +0.20% -9.75%
Apr. 25 Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 16 Tasly Pharmaceutical Group Returns to Profit in 2023 as Operating Income Stays Flat MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 23,252 22,302 23,778 15,988 25,427 22,859 - -
Enterprise Value (EV) 1 29,451 23,121 23,086 14,968 23,635 20,000 19,080 18,155
P/E ratio 23.4 x 19.7 x 10.1 x -63.3 x 23.6 x 19.4 x 15.8 x 15 x
Yield 2.14% 2.23% 2.08% 3.07% 1.94% 2.22% 2.34% 2.6%
Capitalization / Revenue 1.22 x 1.64 x 2.99 x 1.86 x 2.93 x 2.43 x 2.27 x 2.24 x
EV / Revenue 1.55 x 1.7 x 2.9 x 1.74 x 2.72 x 2.13 x 1.9 x 1.78 x
EV / EBITDA 16.7 x 11.2 x 7.32 x 50.8 x 14.2 x 8.65 x 7.64 x 7.37 x
EV / FCF - 16,649,673 x - - - - - -
FCF Yield - 0% - - - - - -
Price to Book 2.1 x 1.87 x 1.83 x 1.3 x 2.06 x 1.71 x 1.59 x 1.48 x
Nbr of stocks (in thousands) 1,507,920 1,507,920 1,500,163 1,485,873 1,493,950 1,488,200 - -
Reference price 2 15.42 14.79 15.85 10.76 17.02 15.36 15.36 15.36
Announcement Date 4/25/20 4/23/21 3/30/22 3/27/23 4/15/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 18,998 13,576 7,952 8,593 8,674 9,407 10,060 10,188
EBITDA 1 1,762 2,062 3,153 294.6 1,663 2,312 2,498 2,462
EBIT 1 1,338 1,472 2,733 -153 1,228 1,530 1,648 1,706
Operating Margin 7.04% 10.85% 34.37% -1.78% 14.16% 16.26% 16.38% 16.75%
Earnings before Tax (EBT) 1 1,331 1,457 2,724 -160.5 1,221 1,608 1,773 1,879
Net income 1 1,001 1,126 2,359 -256.5 1,071 1,179 1,468 1,528
Net margin 5.27% 8.29% 29.66% -2.99% 12.35% 12.53% 14.59% 15%
EPS 2 0.6600 0.7500 1.570 -0.1700 0.7200 0.7900 0.9744 1.022
Free Cash Flow - 1,389 - - - - - -
FCF margin - 10.23% - - - - - -
FCF Conversion (EBITDA) - 67.33% - - - - - -
FCF Conversion (Net income) - 123.34% - - - - - -
Dividend per Share 2 0.3300 0.3300 0.3300 0.3300 0.3300 0.3406 0.3594 0.3997
Announcement Date 4/25/20 4/23/21 3/30/22 3/27/23 4/15/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - - - - - - 2,103 2,049 2,541 2,471 2,896 - -
EBITDA - - - - - - - - - - - - - - -
EBIT - - - - - - - - - - - - - - -
Operating Margin - - - - - - - - - - - - - - -
Earnings before Tax (EBT) - - - - - - - - - - - - - - -
Net income - - - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - - - -
EPS 0.5800 -0.3719 0.1000 0.0500 0.0500 0.1774 0.2900 0.2200 0.0300 0.1976 - - - 0.2800 0.2700
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 3/30/22 4/25/22 8/19/22 10/25/22 3/27/23 4/24/23 8/25/23 10/27/23 4/15/24 4/25/24 - - - - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 6,199 818 - - - - - -
Net Cash position 1 - - 692 1,020 1,792 2,859 3,778 4,703
Leverage (Debt/EBITDA) 3.518 x 0.3968 x - - - - - -
Free Cash Flow - 1,389 - - - - - -
ROE (net income / shareholders' equity) 9.28% 9.76% 18.4% -2.04% 8.75% 8.67% 10.4% 10.2%
ROA (Net income/ Total Assets) 4.07% 5.56% 14.3% - - 7.23% 7.64% 8.2%
Assets 1 24,593 20,253 16,518 - - 16,300 19,205 18,638
Book Value Per Share 2 7.360 7.910 8.660 8.270 8.250 9.000 9.640 10.40
Cash Flow per Share 2 1.110 1.180 1.870 1.520 1.720 0.7400 1.210 1.270
Capex 1 729 403 503 402 668 704 416 405
Capex / Sales 3.84% 2.96% 6.32% 4.68% 7.7% 7.48% 4.13% 3.97%
Announcement Date 4/25/20 4/23/21 3/30/22 3/27/23 4/15/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Tasly Pharmaceutical Group Co., Ltd

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
15.36 CNY
Average target price
12.1 CNY
Spread / Average Target
-21.22%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Alternative Medicine

1st Jan change Capi.
TASLY PHARMACEUTICAL GROUP CO., LTD Stock Tasly Pharmaceutical Group Co., Ltd
-9.75% 3.15B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD. Stock Shijiazhuang Yiling Pharmaceutical Co., Ltd.
-15.13% 4.51B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Stock Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
+2.14% 3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. Stock Shandong Buchang Pharmaceuticals Co., Ltd.
-6.82% 2.42B
HENAN LINGRUI PHARMACEUTICAL CO., LTD. Stock Henan Lingrui Pharmaceutical Co., Ltd.
+47.87% 1.97B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD. Stock Tibet Cheezheng Tibetan Medicine Co., Ltd.
+0.09% 1.65B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD. Stock GuangYuYuan Chinese Herbal Medicine Co., Ltd.
-7.89% 1.68B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD Stock Tianjin Chase Sun Pharmaceutical Co.,Ltd
-12.97% 1.53B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD Stock Zhejiang Jolly Pharmaceutical Co.,LTD
+33.40% 1.38B
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK Stock PT Industri Jamu dan Farmasi Sido Muncul Tbk
+34.29% 1.3B
Alternative Medicine
  1. Stock Market
  2. Equities
  3. 600535 Stock
  4. Financials Tasly Pharmaceutical Group Co., Ltd